NCT05329844已完成不适用
Randomized, Open Label, Two-sequence, Two-treatment, Two-period, Crossover, Single Dose Bioequivalence Study of Vildagliptin Tablets 50 mg of AET Laboratories Pvt. Ltd., India With Galvus 50 mg Tablets of Novartis Europharm Ltd., United Kingdom in Normal Healthy, Adult, Male Human Subjects Under Fasting Conditions.
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 66
- 主要终点
- Cmax of Vildagliptin for the test and reference products
研究概览
简要总结
To evaluate and compare the relative bioavailability and therefore the bioequivalence of Vildagliptin Tablets 50 mg of AET Laboratories Private Limited, India, with GALVUS® 50 mg Tablets of Novartis Europharm Limited, United Kingdom, in normal, healthy, adult, male human subjects under fasting conditions and to evaluate the safety and tolerability of Vildagliptin Tablets 50 mg in normal, healthy, adult, male human subjects under fasting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Male subjects aged between 18 and 45 years (both inclusive).
- •Subjects' weight within the normal range according to normal values for the Body Mass Index (18.5 to 30 kg/m2) with minimum of 50 kg weight.
- •Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within clinically acceptable normal range.
- •Subjects having clinically acceptable 12-lead electrocardiogram (ECG).
- •Subjects having clinically acceptable chest X-Ray.
- •Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine and morphine).
- •Subjects having negative alcohol breath test.
- •Subjects willing to adhere to the protocol requirements and to provide written informed consent.
- •No history or presence of smoking.
- •No history or presence of alcoholism and drug of abuse.
排除标准
- •Hypersensitivity to Vildagliptin or related class of drugs.
- •History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
- •Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 1 month of the study starting.
- •History or presence of asthma, urticaria or other significant allergic reactions.
- •History or presence of significant gastric and/or duodenal ulceration.
- •History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
- •History or presence of cancer.
- •Difficulty with donating blood.
- •Difficulty in swallowing solids like tablets or capsules.
- •Use of any prescribed or OTC medication during last two weeks prior to Dosing in Period
- •Major illness during 3 months before screening.
- •Participation in a drug research study within past 3 months.
- •Donation of blood in the past 3 months before screening.
- •Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
- •History or presence of significant easy bruising or bleeding.
- •History or presence of significant recent trauma.
- •Subjects who have been on an abnormal diet (for whatever reason) during the four weeks preceding the study.
研究组 & 干预措施
Vildagliptin 50 mg Tablet
Experimental
1 tablet of Vildagliptin 50 mg as single-dose administration
干预措施: Vildagliptin 50 MG (Drug)
Galvus 50 mg Tablet
Active Comparator
1 tablet of Galvus 50 mg (each tablet contains 50 mg Vildagliptin) as single-dose administration
干预措施: Vildagliptin 50 MG (Drug)
结局指标
主要结局
Cmax of Vildagliptin for the test and reference products
时间窗: up to 24 hours
The maximum concentration in plasma among observed concentrations at pre-specified time points
AUC0-t of Vildagliptin for the test and the reference products
时间窗: up to 24 hours
The area under the plasma concentration versus time curve from time 0 to the last measured concentration
次要结局
- Tmax of Vildagliptin for the test and the reference products(up to 24 hours)
- Number of treatment-related adverse events (AE) for the test and the reference products as assessed by guidance predefined in the protocol(through study completion, an average of 1 month)
- AUC0-∞ of Vildagliptin for the test and the reference products(up to 24 hours)
- T1/2 of Vildagliptin for the test and the reference products(up to 24 hours)
- Kel of Vildagliptin for the test and the reference products(up to 24 hours)
研究者
相似试验
已完成
1 期
Bioequivalence Study of 8 mg Perindopril Tert-Butylamine / 2.5 mg Indapamide / 10 mg Amlodipine Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide / 10 mg Amlodipine Film-Coated Tablets in Healthy VolunteersBioequivalenceHealthy SubjectsNCT05470764Darnitsa Pharmaceutical Company52
已完成
1 期
Bioequivalence Study of Test and Reference 120 mg Etoricoxib Film-coated Tablets in Healthy VolunteersBioequivalenceHealthy SubjectsNCT05014490Darnitsa Pharmaceutical Company28
已完成
1 期
Bioequivalence Study of 8 mg Perindopril Tert-butylamine / 2.5 mg Indapamide Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide Film-coated Tablets in Healthy VolunteersBioequivalenceHealthy SubjectsNCT05464745Darnitsa Pharmaceutical Company42
已完成
1 期
Bioavailability and Bioequivalence Study of Two Different Sources of OpicaponeParkinson DiseaseNCT03116295Bial - Portela C S.A.56
已完成
不适用
The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Assessed.To Determine Bioequivalence Under Fed ConditionsNCT05337969AET Laboratories Private Limited60